Tetrahydrocannabivarin (THCV) Cannabinoid Research

Tetrahydrocannabivarin (THCV) Research Dashboard

8

Primary Studies

10

Related Studies

18

Total Studies

Clinical Studies

2

Double-blind, placebo-controlled human trials

0

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

4

Animal studies

1

Laboratory studies

Studies by Organ System

No data to display

Studies by Country of Researcher

No data to display

Top Conditions Related to THCV Studies

No data to display

Receptors Associated with THCV Studies

No data to display

THCV Has Shown Proven Effects in Clinical Human Trials for these conditions:

Select New Cannabinoid

Filter Cannabinoid

8 PRIMARY STUDIES | 18 TOTAL STUDIES

Beneficial effects of the phytocannabinoid Δ 9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease

Type of Study: Animal Study

Year of Pub: 2020

Antioxidant and antimicrobial activity of two standardized extracts from a new Chinese accession of non-psychotropic Cannabis sativa L

Type of Study: Laboratory Study

Year of Pub: 2020

Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders

Type of Study: Meta-analysis

Year of Pub: 2019

Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence

Type of Study: Animal Study

Year of Pub: 2019

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study.

Type of Study: Double Blind Human Trial

Year of Pub: 2016

Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers

Type of Study: Double Blind Human Trial

Year of Pub: 2015

The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity.

Type of Study: Animal Study

Year of Pub: 2013

Δ8-Tetrahydrocannabivarin Prevents Hepatic Ischaemia/Reperfusion Injury by Decreasing Oxidative Stress and Inflammatory Responses Through Cannabinoid CB2 Receptors

Type of Study: Animal Study

Year of Pub: 2012

10 RELATED STUDIES | 18 TOTAL STUDIES

Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

Type of Study: Laboratory Study

Year of Pub: 2021

In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

Type of Study: Laboratory Study

Year of Pub: 2020

Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

Type of Study: Meta-analysis

Year of Pub: 2019

Future Aspects for Cannabinoids in Breast Cancer Therapy

Type of Study: Meta-analysis

Year of Pub: 2019

Simultaneous Quantification of 13 Cannabinoids and Metabolites in Human Plasma by Liquid Chromatography Tandem Mass Spectrometry in Adult Epilepsy Patients

Type of Study: Meta-analysis

Year of Pub: 2019

Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary

Type of Study: Meta-analysis

Year of Pub: 2019

Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome

Type of Study: Meta-analysis

Year of Pub: 2019

Molecular Targets of the Phytocannabinoids-A Complex Picture

Type of Study: Meta-analysis

Year of Pub: 2017

Non-THC Cannabinoids Inhibit Prostate Carcinoma Growth In Vitro And In Vivo: Pro-apoptotic Effects And Underlying Mechanisms

Type of Study: Animal Study

Year of Pub: 2013

Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Type of Study: Animal Study

Year of Pub: 2012

Overview - Tetrahydrocannabivarin (THCV)

Description of Tetrahydrocannabivarin (THCV)

Δ9-Tetrahydrocannabivarin (THCV) was discovered in 1971. It belongs to the THC group but produces different effects than THC. A lot of attention is given THCV of late due to the observation that it may be able to produce therapeutic effects in obesity related diabetes especially in contrast to the failed approach with Rimonabant, the CB1 inverse agonist used to treat obesity but then pulled from market due to the potential increased of mood disorders.

Other Names:

Delta 9-Trans-Tetrahydrocannabivarin

Tetrahydrocannabivarin (THCV) Properties and Effects

Affects lipid and sugar metabolism, Antipsychotic effects

Tetrahydrocannabivarin (THCV) Receptor Binding

Recent reports suggest THCV is a tissue specific or dose-dependent (high dose) agonist/(low does) antagonist at CB1 receptors. Recent reports suggest THCV is a tissue specific or dose-dependent (high dose) agonist/(low does) antagonist at CB2 receptors. GPR-55 receptors. TRPV receptors. Serotonin receptors (5-HT1A)

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.